{"classes":[{"categories":[{"measurements":[{"groupId":"OG013","spread":"21","value":"3.639"},{"groupId":"OG014","spread":"42","value":"4.216"},{"groupId":"OG015","spread":"96","value":"2.144"},{"groupId":"OG016","spread":"51","value":"2.277"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"10"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"8"}],"units":"Participants"}],"title":"Total PF-06863135: Cycle 0 Day 1"},{"categories":[{"measurements":[{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.00168 and 0.00282.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.00287 and 0.00439","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.0122 and 0.0133.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"36","value":"0.05363"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.164 and 0.297.","groupId":"OG004","spread":"NA","value":"NA"},{"groupId":"OG005","spread":"27","value":"0.6044"},{"groupId":"OG006","spread":"41","value":"0.8725"},{"groupId":"OG007","spread":"46","value":"0.2866"},{"groupId":"OG008","spread":"24","value":"0.9076"},{"groupId":"OG009","spread":"25","value":"1.220"},{"groupId":"OG010","spread":"42","value":"2.568"},{"groupId":"OG011","spread":"12","value":"3.802"},{"groupId":"OG012","spread":"53","value":"3.620"},{"groupId":"OG013","spread":"18","value":"9.927"},{"groupId":"OG014","spread":"54","value":"8.710"},{"groupId":"OG015","spread":"141","value":"5.513"},{"groupId":"OG016","spread":"36","value":"5.814"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"11"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"9"}],"units":"Participants"}],"title":"Total PF-06863135: Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.475 and 0.624.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 0.219.","groupId":"OG002","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.151 and 0.233.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 0.440.","groupId":"OG004","value":"NA"},{"groupId":"OG005","spread":"8","value":"0.9924"},{"groupId":"OG006","spread":"23","value":"1.684"},{"groupId":"OG007","spread":"55","value":"0.6904"},{"groupId":"OG008","spread":"38","value":"2.108"},{"groupId":"OG009","spread":"24","value":"3.021"},{"groupId":"OG010","spread":"16","value":"5.748"},{"groupId":"OG011","spread":"28","value":"11.92"},{"groupId":"OG012","spread":"26","value":"12.98"},{"groupId":"OG013","spread":"19","value":"25.74"},{"groupId":"OG014","spread":"67","value":"12.03"},{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 16.6.","groupId":"OG015","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 10.8 and 12.0.","groupId":"OG016","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"4"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"2"}],"units":"Participants"}],"title":"Total PF-06863135: Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG013","spread":"59","value":"0.9445"},{"groupId":"OG014","spread":"79","value":"1.087"},{"groupId":"OG015","spread":"83","value":"0.5165"},{"groupId":"OG016","spread":"59","value":"0.8080"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"10"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"9"}],"units":"Participants"}],"title":"Free PF-06863135: Cycle 0 Day 1"},{"categories":[{"measurements":[{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 0.000.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 0.000.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 0.000.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"1.23","value":"0.0008828"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.0760 and 0.153.","groupId":"OG004","spread":"NA","value":"NA"},{"groupId":"OG005","spread":"40","value":"0.1851"},{"groupId":"OG006","spread":"75","value":"0.3015"},{"groupId":"OG007","spread":"36","value":"0.09913"},{"groupId":"OG008","spread":"28","value":"0.2479"},{"groupId":"OG009","spread":"47","value":"0.5916"},{"groupId":"OG010","spread":"131","value":"0.8304"},{"groupId":"OG011","spread":"52","value":"0.9875"},{"groupId":"OG012","spread":"66","value":"0.8266"},{"groupId":"OG013","spread":"106","value":"2.088"},{"groupId":"OG014","spread":"91","value":"2.485"},{"groupId":"OG015","spread":"90","value":"1.185"},{"groupId":"OG016","spread":"76","value":"2.150"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"11"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"9"}],"units":"Participants"}],"title":"Free PF-06863135: Cycle 1 Day 1"},{"categories":[{"measurements":[{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 0.000.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 0.000.","groupId":"OG002","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 0.000 and 0.000.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 0.103.","groupId":"OG004","spread":"NA","value":"NA"},{"groupId":"OG005","spread":"37","value":"0.2855"},{"groupId":"OG006","spread":"4","value":"0.2955"},{"groupId":"OG007","spread":"40","value":"0.1794"},{"groupId":"OG008","spread":"41","value":"0.3998"},{"groupId":"OG009","spread":"79","value":"1.473"},{"groupId":"OG010","spread":"182","value":"1.605"},{"groupId":"OG011","spread":"79","value":"7.981"},{"groupId":"OG012","spread":"156","value":"3.953"},{"groupId":"OG013","spread":"186","value":"11.00"},{"groupId":"OG014","spread":"69","value":"5.323"},{"comment":"Since only 1 participant evaluable, summary statistics could not be calculated. Individual participant data was 2.53.","groupId":"OG015","value":"NA"},{"comment":"Since there were only 2 participants evaluable, summary statistics was not calculated. Individual participants data was 9.65 and 12.1.","groupId":"OG016","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"4"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"2"}],"units":"Participants"}],"title":"Free PF-06863135: Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"12"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"9"}],"units":"Participants"}],"description":"Cmax of PF-06863135 was measured in this outcome measure. Total is free and bound drug in the body.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with relapsed/refractory advanced multiple myeloma (MM) received PF-06863135 at a dose of 0.1 microgram/kilogram (mcg/kg) as an intravenous (IV) infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG000","title":"Part 1: PF-06863135 0.1 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 0.3 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG001","title":"Part 1: PF-06863135 0.3 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 1 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG002","title":"Part 1: PF-06863135 1 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 3 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG003","title":"Part 1: PF-06863135 3 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 10 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG004","title":"Part 1: PF-06863135 10 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 30 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG005","title":"Part 1: PF-06863135 30 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 50 mcg/kg as an IV infusion for 2 hours on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG006","title":"Part 1: PF-06863135 50 mcg/kg IV"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 80 mcg/kg as a subcutaneous (SC) injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG007","title":"Part 1: PF-06863135 80 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 130 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG008","title":"Part 1: PF-06863135 130 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 215 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG009","title":"Part 1: PF-06863135 215 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 360 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG010","title":"Part 1: PF-06863135 360 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 600 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG011","title":"Part 1: PF-06863135 600 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a dose of 1000 mcg/kg as a SC injection on Day 1, 8 and 15 of each 21-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG012","title":"Part 1: PF-06863135 1000 mcg/kg SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 600 mcg/kg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 1000 mcg/kg as a SC injection every week (Q1W) on Day 1, 8, 15 and 22 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG013","title":"Part 1.1: PF-06863135 Priming Cohort Q1W SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 600 mcg/kg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 1000 mcg/kg as a SC injection every 2 weeks (Q2W) on Day 1 and 15 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG014","title":"Part 1.1: PF-06863135 Priming Cohort Q2W SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 32 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 44 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 along with lenalidomide at dose of 15 mg, orally, daily on Days 1-21 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG015","title":"Part 1C: PF-06863135 + Lenalidomide SC"},{"description":"Participants with relapsed/refractory advanced MM received PF-06863135 at a priming dose of 32 mcg as a SC injection, on Day 1 of Cycle 0. Participants received maintenance dose of 44 mcg as a SC injection Q1W on Day 1, 8, 15 and 22 along with pomalidomide at dose of 4 mg, orally, daily on Days 1-21 of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurred first.","id":"OG016","title":"Part 1D: PF-06863135 + Pomalidomide SC"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) parameter analysis set was defined as all enrolled participants treated who had sufficient information to estimate at least 1 of the PF- 06863135 PK parameters of interest. All participants reported under \"Number of Participants Analyzed\" contributed data to the table; however, may not have evaluable data for every row. Here, \"Number Analyzed\" signifies number of participants evaluable at specified rows.","reportingStatus":"POSTED","timeFrame":"0 hours (h) on Day 1 of Cycle (C) 0; 0, 2 and 4h on Day 1 of C1 and C2","title":"Part 1: Maximum Observed Concentration (Cmax) of PF-06863135","type":"SECONDARY","unitOfMeasure":"Micrograms per milliliter"}